<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Clinical Neuroscience</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9D425BE3-C541-400E-95BE-EB64372839DC"><gtr:id>9D425BE3-C541-400E-95BE-EB64372839DC</gtr:id><gtr:firstName>Jacqueline</gtr:firstName><gtr:otherNames>S</gtr:otherNames><gtr:surname>de Belleroche</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/41068207-27FE-4720-AF41-A707BEE62ACE"><gtr:id>41068207-27FE-4720-AF41-A707BEE62ACE</gtr:id><gtr:firstName>Ammar</gtr:firstName><gtr:surname>Al-Chalabi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/62211B96-56AF-4672-8BA7-754E3F0AC07B"><gtr:id>62211B96-56AF-4672-8BA7-754E3F0AC07B</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2C8449A4-22C8-4857-A9A3-BF4A17360F53"><gtr:id>2C8449A4-22C8-4857-A9A3-BF4A17360F53</gtr:id><gtr:firstName>Cathryn</gtr:firstName><gtr:surname>Lewis</gtr:surname><gtr:orcidId>0000-0002-8249-8476</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900688"><gtr:id>D48E827E-CCB1-42CF-8329-2D385294AE76</gtr:id><gtr:title>Next Generation Gene Hunting in Amyotrophic Lateral Sclerosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900688</gtr:grantReference><gtr:abstractText>There are no effective treatments for amyotrophic lateral aclerosis (ALS) because so little is known about what causes it. In most instances ALS appears out of the blue (called sporadic ALS) but in 10% the disease runs in families (familial ALS) due to a single defective gene, passed down from generation to generation. Four genes are known to cause ALS (SOD1, TARDBP, FUS and ANG) but they account for only 25% of all familial and 7% of sporadic ALS patients. The cause of the disease in 90% of patients is unknown but a genetic basis is strongly implicated.

The ?Next Generation? of DNA technology has transformed what can be achieved in genetic research. The human genome mapping project published in 2000 one person?s entire genetic code. It took 15 years and cost #~300 million. This can now be done in 1 month for #~10,000. This grant application aims to harness the extraordinary power of these new research tools in a global gene hunting effort.

Only ~2% of the human genetic code provides the blueprint for making proteins (the building blocks of all cells). Mutations in these genes accounts for most human diseases. Revolutionary DNA capture methods mean that we can pull out the protein encoding 2% of genes for further analysis. Single molecule DNA sequencing allows us to read the spelling of millions of different DNA fragments and rapidly identify the disease-causing spelling mistakes.

We are focusing our most intensive sequencing on DNA from 100 families and comparisons made to healthy controls. Potential mutations will be then screened in DNA samples held by a global network of ALS researchers, ( 2,000 familial and 10,000 sporadic samples). For the 30% of genes that are not covered by DNA capture methods we will identify chromosomal regions that contain ancient mutations and target genes implicated in known pathological ALS pathways.

Screening of new ALS genes can be offered to at-risk families and sporadic patients who are worried about the risk to other family members. The gene mutations we identify can be introduced into cells and mice allowing us to study the harmful effects of ALS gene mutations. This will dramatically improve our understanding of the underlying disease mechanisms and develop drugs capable of arresting the disease process and even preventing it occurring in genetically susceptible individuals.</gtr:abstractText><gtr:technicalSummary>Amyotrophic lateral sclerosis (ALS, also known as motor neurone disease) causes progressive paralysis and takes the lives of 1,200 people in the UK every year. There are no effective treatments and little is known about its causes. Most ALS is sporadic but in 10% it is clearly familial (FALS), due to a single gene mutation inherited in an autosomal dominant fashion. Clinically and pathologically, familial and sporadic ALS are indistinguishable and many cases of sporadic ALS may be caused by gene defects with low penetrance. Most genetic neurodegenerative disorders are due to mutations that cause a change in the amino acid sequence. Four genes known to cause ALS account for only 25% of familial and 7% of sporadic ALS. We aim to identify the remaining FALS genes in order to offer comprehensive counselling and gene testing to at-risk families and concerned individuals with apparently sporadic disease. This will dramatically improve our understanding of disease pathogenesis and significantly advance drug discovery.

Here we propose an unprecedented gene hunting effort using revolutionary techniques including DNA capture, deep resequencing and high-density SNP genotyping. Using an initial cohort of cultured lymphoblast lines from 100 FALS cases we will extract high quality DNA, RNA and protein. Using the Nimblegen 2.1m array we will capture ~180,000 exons (comprising ~70% of the human genome) for sequencing on the Solexa GAII. We will also perform high density SNP genotyping on the Illumina Quad650 arrays looking for ancient common founder mutations. Lastly we will target genes implicated in pathways implicated in ALS pathogenesis not represented in the Nimblegen arrays.

Our five criteria for prioritising variants are those that (i) change the amino acid sequence, (ii) segregate with disease within kindreds, (iii) affect multiple families, (iv) have multiple mutations in multiple families and (v) have a low mutation frequency in multiple control populations. Variants that meet these criteria will be confirmed by Sanger sequencing and compared to the controls in SNP databases. Genes with confirmed mutations will be screened in a second cohort of local familial (200) and sporadic cases (2,000). We will notify our FALS Network partners of the most promising genes (frequency 1%) and request screening in their FALS and SALS cohorts to determine their global frequency and ethnic variation. Having identified mutations with a high likelihood of pathogenicity we will test for toxicity in cell lines, primary neurons and simple animal models (embryonic chicken and zebrafish).</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1626130</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient and Carers meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>914D7963-0EAD-4B48-98AE-70B0112EF26D</gtr:id><gtr:impact>Each meeting has 40-60 attendees and lasts 1.5 hours with talk and questions

Patients have come to our laboratory open day and are actively fundraising to create a studentship</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ask the Experts Panel at International Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BBDA3E65-3964-4C23-8178-27ECA73C834B</gtr:id><gtr:impact>A live audience and online audience watched a presentation and then asked questions on ALS research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=U98WU4Zzu8s</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centre Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>4663883F-5B0A-4B1B-B06A-F870AF3514C0</gtr:id><gtr:impact>Our Open Day is for patients and carers with approximately 150 attendees. We organise 8 laboratory demonstrations presented by PhD students and postdoctoral researchers around which small groups (6-8 persons) circulate. We also have a group of about 12 sixth form students who perform a laboratory experiment. At the end of the day the sixth formers present their results to the who audience and this is followed by an &amp;quot;Any Questions&amp;quot; session with clinical and non-clinical experts answering questions from the visitors.

The Open Day has now been run on three occasions and each time has received universal acclaim from visitors. The report is also made available on our web site.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MNDA information video on our research</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5FFB8CD7-CBB1-403F-A839-B2A4B7B341A6</gtr:id><gtr:impact>A YouTube video posted also on the Motor Neurone Disease Association website, describing our research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://youtu.be/tKz81aFVB04</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented to Members of Parliament</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>E14C080B-AA23-4C08-A056-609096E5579D</gtr:id><gtr:impact>Presented to parliamentary parties

Legeislation changed</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Many media interviews TV, Radio, Newspapers, Radio</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>324C3C93-FC39-4889-BD3F-956217E6EE03</gtr:id><gtr:impact>Many media interviews TV, Radio, Newspapers, Radio

Legislation modified</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Multi-site Phosphorylation Assays for Tau Protein and their relevance to Alzheimer's disease and other neurological disorders</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>36F57FEC-315B-4AB0-973C-B5A406952BC5</gtr:id><gtr:impact>Poster presentation at American Society of Mass Spectrometry conference

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Peterborough</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>F9C1FA5B-9D69-4251-BE58-05E72C087F7B</gtr:id><gtr:impact>Lectured to school students and informal chat

Enthusiastic discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>11559048-2C5D-4A09-87C3-CA42FF369C89</gtr:id><gtr:impact>Public lecture on the genetics and biology of motor neuron disease</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Use of Mass Spectrometry for Multi-site Phosphorylation Assays for Tau Protein</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>F0AD9D39-B115-4A16-B4E8-7967EFD4C195</gtr:id><gtr:impact>Poster presentation at International Conference on Alzheimer's Disease, Chicago

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Broadcast news items on new gene discoveries</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62C543D9-F20F-4463-A56B-46FC9B23203E</gtr:id><gtr:impact>Interviews with BBC World (live TV interview), ITV News (recorded TV), Channel 5 News (recorded TV), BBC Radio London (live radio) and others. Example URL below</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://twitter.com/ammaralchalabi/status/758321315698933760</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient and Carers meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>C37C342F-1FEF-474E-8840-538A1784E2D8</gtr:id><gtr:impact>40-60 Patients and Carers lasting 1.5 hours of talk and discussion

Members of the audience are fundraising for a studentship for my laboratory</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture on motor neuron disease research</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>903E505A-B153-48AB-BF5D-53BC99C4CF97</gtr:id><gtr:impact>I spoke at a dinner hosted by the MND Association for major donors at the Royal Institution</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>General research dissemination videos on YouTube</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7B8057DB-7724-4823-8322-53FE2AC3C6D3</gtr:id><gtr:impact>Multiple videos on YouTube, responding to interviews on ALS research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/results?search_query=ammar+al-chalabi+als</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sleep and circadian rhythm disorder in Parkinson's Disease:  association with hallucinations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>7C367EEF-47A9-480A-ADBC-07D92A04E1D7</gtr:id><gtr:impact>A world conference on sleep.

Received a citation award.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>666323</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Spanish National Research Council (CSIC)</gtr:department><gtr:description>Programme Grant FP7</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>3C580739-733A-45F7-8F26-D469501FEC9E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87502</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MNDA studentship</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>607C4338-560E-406C-A5D9-298D83EA3F61</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Darwin Trust of Edinburgh</gtr:department><gtr:description>Studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Society for the History of Science (BSHS)</gtr:fundingOrg><gtr:id>14DA6CED-CA2F-40F5-B64B-3C35E29C8AD1</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Psychiatry Research Trust</gtr:department><gtr:description>PhD Studentship</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Institute of Psychiatry (IoP)</gtr:fundingOrg><gtr:id>153F74F6-C3AA-4872-8BA4-A6DA8DE18591</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Biomedical Sciences Institute PhD Studentship</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>King's College London (KCL)</gtr:fundingOrg><gtr:id>470C183F-2171-42A2-A9C3-7F5640EBB6DA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sumission to Parliamentary Science and Technology Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>CA6B8F32-ACBE-4665-BA1D-F1AF9C9C7E08</gtr:id><gtr:impact>Permitted the use of hybrid embryos in research in UK</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B007AF9-23B5-4276-9FED-0C0E1905BD80"><gtr:id>2B007AF9-23B5-4276-9FED-0C0E1905BD80</gtr:id><gtr:title>A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b676a228ca42acafedbad61b533efdcc"><gtr:id>b676a228ca42acafedbad61b533efdcc</gtr:id><gtr:otherNames>Wills AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5649D82A-4D47-4561-96FA-3CC78BE5A16B"><gtr:id>5649D82A-4D47-4561-96FA-3CC78BE5A16B</gtr:id><gtr:title>Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a7bfa806ecaa3aa93efd2103aa2e758"><gtr:id>0a7bfa806ecaa3aa93efd2103aa2e758</gtr:id><gtr:otherNames>Cirulli ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/263FFB8C-5CBC-45B3-9406-85C7663674F1"><gtr:id>263FFB8C-5CBC-45B3-9406-85C7663674F1</gtr:id><gtr:title>Association studies indicate that protein disulfide isomerase is a risk factor in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ca9888509a2e1aa2bdbb5ae3b44a8e0"><gtr:id>4ca9888509a2e1aa2bdbb5ae3b44a8e0</gtr:id><gtr:otherNames>Kwok CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55508EDE-21F7-4ABD-8FEB-81190C7B3D61"><gtr:id>55508EDE-21F7-4ABD-8FEB-81190C7B3D61</gtr:id><gtr:title>Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4764aa823b7a020b3590bce2cc799303"><gtr:id>4764aa823b7a020b3590bce2cc799303</gtr:id><gtr:otherNames>Kent L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECC5244C-32AD-414C-8A8D-80430751304A"><gtr:id>ECC5244C-32AD-414C-8A8D-80430751304A</gtr:id><gtr:title>Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a46cc13f73dd87b9293e1cd22958c7c"><gtr:id>6a46cc13f73dd87b9293e1cd22958c7c</gtr:id><gtr:otherNames>Stepto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FBF256E8-56CE-4442-A8EF-50CF853A1E67"><gtr:id>FBF256E8-56CE-4442-A8EF-50CF853A1E67</gtr:id><gtr:title>A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF1EF192-27D3-426A-99D8-89C39ACC7349"><gtr:id>CF1EF192-27D3-426A-99D8-89C39ACC7349</gtr:id><gtr:title>Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39D2F8C2-4927-4C87-B329-719171AC178A"><gtr:id>39D2F8C2-4927-4C87-B329-719171AC178A</gtr:id><gtr:title>Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57BD6139-8B62-4783-8071-253BA61E5D41"><gtr:id>57BD6139-8B62-4783-8071-253BA61E5D41</gtr:id><gtr:title>Analysis of alternative splicing associated with aging and neurodegeneration in the human brain.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8c5b5cbc90e5661dfa072a51bb8ca2c"><gtr:id>b8c5b5cbc90e5661dfa072a51bb8ca2c</gtr:id><gtr:otherNames>Tollervey JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78EBEB60-ACEA-400A-972D-536F12EC862E"><gtr:id>78EBEB60-ACEA-400A-972D-536F12EC862E</gtr:id><gtr:title>The role of variation at A?PP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/719950cfe57960088e8c4cb5aaf09b14"><gtr:id>719950cfe57960088e8c4cb5aaf09b14</gtr:id><gtr:otherNames>Gerrish A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C995886-C9EE-47F8-979D-310A1AD0A1E8"><gtr:id>8C995886-C9EE-47F8-979D-310A1AD0A1E8</gtr:id><gtr:title>Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/de2408812a9d6aa79cb920c86fdae47f"><gtr:id>de2408812a9d6aa79cb920c86fdae47f</gtr:id><gtr:otherNames>Shatunov A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36484CFD-A167-4B44-81A2-DF7A793F471C"><gtr:id>36484CFD-A167-4B44-81A2-DF7A793F471C</gtr:id><gtr:title>Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e078c74958f5d34c29d138c303e544f8"><gtr:id>e078c74958f5d34c29d138c303e544f8</gtr:id><gtr:otherNames>Landers JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BC4FA8EC-A7DD-4839-890D-94D32ACF9787"><gtr:id>BC4FA8EC-A7DD-4839-890D-94D32ACF9787</gtr:id><gtr:title>The role of copy number variation in susceptibility to amyotrophic lateral sclerosis: genome-wide association study and comparison with published loci.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a94bd817e0697ab1ede1ac552afec188"><gtr:id>a94bd817e0697ab1ede1ac552afec188</gtr:id><gtr:otherNames>Wain LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7817C638-AB43-4115-B69F-C2E686BE3200"><gtr:id>7817C638-AB43-4115-B69F-C2E686BE3200</gtr:id><gtr:title>Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c562354aece4404287db767cad69712b"><gtr:id>c562354aece4404287db767cad69712b</gtr:id><gtr:otherNames>Rogelj B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/974EEE23-9010-4279-82F3-AF2C9F3B04DD"><gtr:id>974EEE23-9010-4279-82F3-AF2C9F3B04DD</gtr:id><gtr:title>Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a885c902c57eeb35d266c592227182d7"><gtr:id>a885c902c57eeb35d266c592227182d7</gtr:id><gtr:otherNames>van Es MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/332E4DA1-FA56-402D-9828-D0ACD20C0B70"><gtr:id>332E4DA1-FA56-402D-9828-D0ACD20C0B70</gtr:id><gtr:title>Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea19fc76f7804dd1a81c51c7e7996ae7"><gtr:id>ea19fc76f7804dd1a81c51c7e7996ae7</gtr:id><gtr:otherNames>Bogaert E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2509813E-2C73-4A6F-88EC-F2F307D311CF"><gtr:id>2509813E-2C73-4A6F-88EC-F2F307D311CF</gtr:id><gtr:title>Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E6F4F9E-9869-430E-8CFC-908B58E8C63B"><gtr:id>2E6F4F9E-9869-430E-8CFC-908B58E8C63B</gtr:id><gtr:title>No association of DPP6 with amyotrophic lateral sclerosis in an Italian population.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61F9A40B-EE1D-41F6-8448-AF87F7C253F7"><gtr:id>61F9A40B-EE1D-41F6-8448-AF87F7C253F7</gtr:id><gtr:title>Unpicking neurodegeneration in a dish with human pluripotent stem cells: one cell type at a time.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8270B0C4-A69F-435E-BCA2-85B535877CDD"><gtr:id>8270B0C4-A69F-435E-BCA2-85B535877CDD</gtr:id><gtr:title>Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c3f5a5bc7ae9744e72b93546e48cb6f"><gtr:id>7c3f5a5bc7ae9744e72b93546e48cb6f</gtr:id><gtr:otherNames>Ahmeti KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E65ABB16-20E8-4505-8A54-42C87A47FD7C"><gtr:id>E65ABB16-20E8-4505-8A54-42C87A47FD7C</gtr:id><gtr:title>The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A62B7DFB-E604-4FB8-858D-420C9725475D"><gtr:id>A62B7DFB-E604-4FB8-858D-420C9725475D</gtr:id><gtr:title>Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/260fa42b858aee5033974fabe5a89dd6"><gtr:id>260fa42b858aee5033974fabe5a89dd6</gtr:id><gtr:otherNames>King A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB426949-5D53-4F91-99DD-0DCF20059434"><gtr:id>CB426949-5D53-4F91-99DD-0DCF20059434</gtr:id><gtr:title>Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B10BEF5-A105-4F91-ABC9-23D834B8DC06"><gtr:id>1B10BEF5-A105-4F91-ABC9-23D834B8DC06</gtr:id><gtr:title>The risk to relatives of patients with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db7eed95c8d8823c4695be423aefb76b"><gtr:id>db7eed95c8d8823c4695be423aefb76b</gtr:id><gtr:otherNames>Hanby MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54E59EAC-39FE-461A-9E4A-C1B6B27B6D66"><gtr:id>54E59EAC-39FE-461A-9E4A-C1B6B27B6D66</gtr:id><gtr:title>TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fa1218e77e38a903ec46a6c73ad708a4"><gtr:id>fa1218e77e38a903ec46a6c73ad708a4</gtr:id><gtr:otherNames>Pensato V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BA0F9537-4EC4-49DE-ABC6-2E92E6373BB4"><gtr:id>BA0F9537-4EC4-49DE-ABC6-2E92E6373BB4</gtr:id><gtr:title>Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/52940ec2fe08219598d16e61c9f32c80"><gtr:id>52940ec2fe08219598d16e61c9f32c80</gtr:id><gtr:otherNames>Niblock M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77E6E033-AAC4-4A83-BE0C-08390133B92C"><gtr:id>77E6E033-AAC4-4A83-BE0C-08390133B92C</gtr:id><gtr:title>The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5a1becffcc1571868d22b707ce216d4c"><gtr:id>5a1becffcc1571868d22b707ce216d4c</gtr:id><gtr:otherNames>Wong CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2D5646C-A4B5-432C-8743-1401ABD20D9E"><gtr:id>C2D5646C-A4B5-432C-8743-1401ABD20D9E</gtr:id><gtr:title>Homozygosity analysis in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb5ecebb0a95326732850cb51e132dc6"><gtr:id>bb5ecebb0a95326732850cb51e132dc6</gtr:id><gtr:otherNames>Mok K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A989CF0-AD98-4F06-9329-FA75EBEABBB5"><gtr:id>7A989CF0-AD98-4F06-9329-FA75EBEABBB5</gtr:id><gtr:title>Comment on &amp;quot;Drug screening for ALS using patient-specific induced pluripotent stem cells&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c0033dc734f06165d7061a9236c4adef"><gtr:id>c0033dc734f06165d7061a9236c4adef</gtr:id><gtr:otherNames>Bilican B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB7F795D-69A2-465A-B73A-4D8D8FEC9F17"><gtr:id>DB7F795D-69A2-465A-B73A-4D8D8FEC9F17</gtr:id><gtr:title>Tar DNA-binding protein-43 (TDP-43) regulates axon growth in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0737bcb5a8ebef94755f6214dfe82972"><gtr:id>0737bcb5a8ebef94755f6214dfe82972</gtr:id><gtr:otherNames>Tripathi VB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D418D33-84F5-49DF-8F69-87EA1AACB3AD"><gtr:id>5D418D33-84F5-49DF-8F69-87EA1AACB3AD</gtr:id><gtr:title>C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D08681DC-D9B1-4F3E-BD33-78A5189BB323"><gtr:id>D08681DC-D9B1-4F3E-BD33-78A5189BB323</gtr:id><gtr:title>No association of genetic variants in BDNF with major depression: a meta- and gene-based analysis.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c2bdd3a817ea3669bca79a9ef2335e60"><gtr:id>c2bdd3a817ea3669bca79a9ef2335e60</gtr:id><gtr:otherNames>Gyekis JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C912F073-C914-4B4F-891A-ABEEB68FCC05"><gtr:id>C912F073-C914-4B4F-891A-ABEEB68FCC05</gtr:id><gtr:title>Gene discovery in amyotrophic lateral sclerosis: implications for clinical management.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A10D5E77-8FE4-470E-9C1B-51CE10CA86E4"><gtr:id>A10D5E77-8FE4-470E-9C1B-51CE10CA86E4</gtr:id><gtr:title>Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50945e50d1e1c6d39e7dc9ad7322b46b"><gtr:id>50945e50d1e1c6d39e7dc9ad7322b46b</gtr:id><gtr:otherNames>Ticozzi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE2FB0BD-A86D-44F9-80D5-D748A8BE4FD4"><gtr:id>FE2FB0BD-A86D-44F9-80D5-D748A8BE4FD4</gtr:id><gtr:title>An estimate of amyotrophic lateral sclerosis heritability using twin data.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7bc8538c82db76d6e2482ddeeb2d3d0"><gtr:id>d7bc8538c82db76d6e2482ddeeb2d3d0</gtr:id><gtr:otherNames>Al-Chalabi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF5BA5B7-4FCF-4574-B251-54FFB493FEEC"><gtr:id>AF5BA5B7-4FCF-4574-B251-54FFB493FEEC</gtr:id><gtr:title>Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d024ea21137b0b872fa04d61a2139840"><gtr:id>d024ea21137b0b872fa04d61a2139840</gtr:id><gtr:otherNames>Hortob?gyi T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BF30A80-F957-45E1-80F7-16C7476007CC"><gtr:id>5BF30A80-F957-45E1-80F7-16C7476007CC</gtr:id><gtr:title>Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/39C6F7EB-E38C-434F-BC10-3F26A694A154"><gtr:id>39C6F7EB-E38C-434F-BC10-3F26A694A154</gtr:id><gtr:title>Establishing the UK DNA Bank for motor neuron disease (MND).</gtr:title><gtr:parentPublicationTitle>BMC genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d800fe2353c2fd435d4e9f68af2a0c5d"><gtr:id>d800fe2353c2fd435d4e9f68af2a0c5d</gtr:id><gtr:otherNames>Smith L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2156</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/48673D79-9004-4FE9-B02B-90354426D519"><gtr:id>48673D79-9004-4FE9-B02B-90354426D519</gtr:id><gtr:title>A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac5f45d8a5f9965eb360b3f6697fe0a9"><gtr:id>ac5f45d8a5f9965eb360b3f6697fe0a9</gtr:id><gtr:otherNames>Akimoto C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5335A49-45CA-4861-A240-0027F9BC6905"><gtr:id>A5335A49-45CA-4861-A240-0027F9BC6905</gtr:id><gtr:title>Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b52384d0266bc60ddab21c962b93cc25"><gtr:id>b52384d0266bc60ddab21c962b93cc25</gtr:id><gtr:otherNames>Hollingworth P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A0E01C6-DF88-4024-8CB1-00A92585F142"><gtr:id>9A0E01C6-DF88-4024-8CB1-00A92585F142</gtr:id><gtr:title>Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c831250c6d5af43302dbd12e99b4fb6"><gtr:id>1c831250c6d5af43302dbd12e99b4fb6</gtr:id><gtr:otherNames>Lee YB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF29A64E-AE1A-4ED5-A4AB-E1EE2432D8A1"><gtr:id>EF29A64E-AE1A-4ED5-A4AB-E1EE2432D8A1</gtr:id><gtr:title>The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3617d8d8a839d289a3d354c415cb2d67"><gtr:id>3617d8d8a839d289a3d354c415cb2d67</gtr:id><gtr:otherNames>Lill CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/350FE600-1151-4F4F-B089-605E375BB9F0"><gtr:id>350FE600-1151-4F4F-B089-605E375BB9F0</gtr:id><gtr:title>Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35d6cd3c48df4ba250f8982f7b132101"><gtr:id>35d6cd3c48df4ba250f8982f7b132101</gtr:id><gtr:otherNames>Zimon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB3EB71A-48EA-4A79-8AD9-58075AA83022"><gtr:id>AB3EB71A-48EA-4A79-8AD9-58075AA83022</gtr:id><gtr:title>Mutation analysis of VCP in British familial and sporadic amyotrophic lateral sclerosis patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8697d5274b04347d52a7ffa40e09bb2c"><gtr:id>8697d5274b04347d52a7ffa40e09bb2c</gtr:id><gtr:otherNames>Miller JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/962249F9-AA4D-4586-8568-F2DC7F721C2C"><gtr:id>962249F9-AA4D-4586-8568-F2DC7F721C2C</gtr:id><gtr:title>H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6883810a16e61c37ff340736f6cdf792"><gtr:id>6883810a16e61c37ff340736f6cdf792</gtr:id><gtr:otherNames>van Rheenen W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC4C0DBE-44D2-4291-A20A-7FCE274A5404"><gtr:id>FC4C0DBE-44D2-4291-A20A-7FCE274A5404</gtr:id><gtr:title>Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/59ac40b969c64db850e438e12bb3e323"><gtr:id>59ac40b969c64db850e438e12bb3e323</gtr:id><gtr:otherNames>Jones L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4A98A4F-E0C0-407E-992F-81BD03875EBD"><gtr:id>A4A98A4F-E0C0-407E-992F-81BD03875EBD</gtr:id><gtr:title>Latent cluster analysis of ALS phenotypes identifies prognostically differing groups.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11fc725be9193e0c1332b674cfa73b21"><gtr:id>11fc725be9193e0c1332b674cfa73b21</gtr:id><gtr:otherNames>Ganesalingam J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8EC7C7F-36BE-4D14-A053-B55CE59B5918"><gtr:id>D8EC7C7F-36BE-4D14-A053-B55CE59B5918</gtr:id><gtr:title>Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ecfd0497d0375c0a88359b331f4d279"><gtr:id>6ecfd0497d0375c0a88359b331f4d279</gtr:id><gtr:otherNames>Alami NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6C3FD9C-0208-45EA-9E3B-96518B585316"><gtr:id>B6C3FD9C-0208-45EA-9E3B-96518B585316</gtr:id><gtr:title>No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc23875dbdf591dfec98dd2283598bc3"><gtr:id>cc23875dbdf591dfec98dd2283598bc3</gtr:id><gtr:otherNames>Goris A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/902BF295-F11D-4BC8-85D7-4D56943D6039"><gtr:id>902BF295-F11D-4BC8-85D7-4D56943D6039</gtr:id><gtr:title>NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa8dc20d96363a2f4e574a132c76feaf"><gtr:id>aa8dc20d96363a2f4e574a132c76feaf</gtr:id><gtr:otherNames>Kenna KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/743D1537-A5CB-4167-8E45-6A2297477F5A"><gtr:id>743D1537-A5CB-4167-8E45-6A2297477F5A</gtr:id><gtr:title>Evidence of an environmental effect on survival in ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c398b2323889da25d02c67f44bc8075"><gtr:id>4c398b2323889da25d02c67f44bc8075</gtr:id><gtr:otherNames>Keren N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/82493C30-0264-4F54-9263-3FEA740A35AF"><gtr:id>82493C30-0264-4F54-9263-3FEA740A35AF</gtr:id><gtr:title>C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4bc40f7ec51e8c45e1a0d464e57ce8e5"><gtr:id>4bc40f7ec51e8c45e1a0d464e57ce8e5</gtr:id><gtr:otherNames>Rooney J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/07385D37-601E-4BEA-B87B-B3BCFAA26CA9"><gtr:id>07385D37-601E-4BEA-B87B-B3BCFAA26CA9</gtr:id><gtr:title>Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9dac006df65aa6fc3664b1b55668fc4f"><gtr:id>9dac006df65aa6fc3664b1b55668fc4f</gtr:id><gtr:otherNames>Simpson CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57102E78-BAFC-4829-B20B-7062F17C225D"><gtr:id>57102E78-BAFC-4829-B20B-7062F17C225D</gtr:id><gtr:title>Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b00d5c326cc86493597c8e738e15c9b9"><gtr:id>b00d5c326cc86493597c8e738e15c9b9</gtr:id><gtr:otherNames>Kim HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6647107A-DE7E-4034-B80A-B9EA0436EC35"><gtr:id>6647107A-DE7E-4034-B80A-B9EA0436EC35</gtr:id><gtr:title>Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/107e692c5cbfdd08a4bdfa319afca3cb"><gtr:id>107e692c5cbfdd08a4bdfa319afca3cb</gtr:id><gtr:otherNames>Vance C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88F9FBA7-1678-45EA-BF98-239BBC624179"><gtr:id>88F9FBA7-1678-45EA-BF98-239BBC624179</gtr:id><gtr:title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a9310cf284c8313db35d3785d3e32077"><gtr:id>a9310cf284c8313db35d3785d3e32077</gtr:id><gtr:otherNames>Harold D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/681504FA-8A4C-4CDC-9C30-C18B06E53EB3"><gtr:id>681504FA-8A4C-4CDC-9C30-C18B06E53EB3</gtr:id><gtr:title>ATXN2 trinucleotide repeat length correlates with risk of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fdc6e29ff1fbfb82d08db9aa811d9c11"><gtr:id>fdc6e29ff1fbfb82d08db9aa811d9c11</gtr:id><gtr:otherNames>Sproviero W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E96DC290-DFF6-47AD-B84E-FC730B66B65F"><gtr:id>E96DC290-DFF6-47AD-B84E-FC730B66B65F</gtr:id><gtr:title>Interaction between PON1 and population density in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Neuroreport</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93dc99c98b59b49150ea537d5c4c070a"><gtr:id>93dc99c98b59b49150ea537d5c4c070a</gtr:id><gtr:otherNames>Diekstra FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-4965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F673607-32B6-41C3-A97E-1078375EA562"><gtr:id>7F673607-32B6-41C3-A97E-1078375EA562</gtr:id><gtr:title>An evaluation of a SVA retrotransposon in the FUS promoter as a transcriptional regulator and its association to ALS.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3108c31a0519408ba70fe51961bbba10"><gtr:id>3108c31a0519408ba70fe51961bbba10</gtr:id><gtr:otherNames>Savage AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/502E9392-317F-4F1F-A948-BA3CECC61B5D"><gtr:id>502E9392-317F-4F1F-A948-BA3CECC61B5D</gtr:id><gtr:title>Neuromuscular disease: new insights and avenues for therapy.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f5ee2d92393641a7087d03d8fb52781"><gtr:id>2f5ee2d92393641a7087d03d8fb52781</gtr:id><gtr:otherNames>Scotter EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/80F8E920-6B12-41E5-88CD-C7C9900D5D35"><gtr:id>80F8E920-6B12-41E5-88CD-C7C9900D5D35</gtr:id><gtr:title>VCP mutations are not a major cause of familial amyotrophic lateral sclerosis in the UK.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ca9888509a2e1aa2bdbb5ae3b44a8e0"><gtr:id>4ca9888509a2e1aa2bdbb5ae3b44a8e0</gtr:id><gtr:otherNames>Kwok CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6D9B5DD-4E82-48A4-B2C9-DB617498C49C"><gtr:id>B6D9B5DD-4E82-48A4-B2C9-DB617498C49C</gtr:id><gtr:title>Screening for OPTN mutations in a cohort of British amyotrophic lateral sclerosis patients.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b92e53040750a2ced7a4b23f1f0a783"><gtr:id>9b92e53040750a2ced7a4b23f1f0a783</gtr:id><gtr:otherNames>Johnson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99C77F25-98C4-4B67-8457-AE2F40BBC827"><gtr:id>99C77F25-98C4-4B67-8457-AE2F40BBC827</gtr:id><gtr:title>Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8150F50D-FC73-4E01-B00B-979DF168B082"><gtr:id>8150F50D-FC73-4E01-B00B-979DF168B082</gtr:id><gtr:title>Stratified gene expression analysis identifies major amyotrophic lateral sclerosis genes.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/189b1ab3fec05c8e5670388f3356335d"><gtr:id>189b1ab3fec05c8e5670388f3356335d</gtr:id><gtr:otherNames>Jones AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D2029D23-BDD8-4919-B705-C47810D992EB"><gtr:id>D2029D23-BDD8-4919-B705-C47810D992EB</gtr:id><gtr:title>Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a6e554bc59d628ea7e59537f8090ec1c"><gtr:id>a6e554bc59d628ea7e59537f8090ec1c</gtr:id><gtr:otherNames>Gaastra B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BFE90816-0AB3-4D3E-B268-12C395EC00E0"><gtr:id>BFE90816-0AB3-4D3E-B268-12C395EC00E0</gtr:id><gtr:title>Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6883810a16e61c37ff340736f6cdf792"><gtr:id>6883810a16e61c37ff340736f6cdf792</gtr:id><gtr:otherNames>van Rheenen W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4AAD53A-2F4C-4D50-942C-88D3F7F23157"><gtr:id>E4AAD53A-2F4C-4D50-942C-88D3F7F23157</gtr:id><gtr:title>p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73513a14720b4cc1a2b1b206959c4d28"><gtr:id>73513a14720b4cc1a2b1b206959c4d28</gtr:id><gtr:otherNames>Al-Sarraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E57D1349-8BA8-45A0-82AE-608629E9DD3F"><gtr:id>E57D1349-8BA8-45A0-82AE-608629E9DD3F</gtr:id><gtr:title>Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/62f19520245730027ecb4972794f9589"><gtr:id>62f19520245730027ecb4972794f9589</gtr:id><gtr:otherNames>Vrabec K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0EC34C8-2DBC-41B2-9F6E-56C29E286ACF"><gtr:id>E0EC34C8-2DBC-41B2-9F6E-56C29E286ACF</gtr:id><gtr:title>Novel mutations support a role for Profilin 1 in the pathogenesis of ALS.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE7A5770-6DF6-4825-BD56-2A5039CCD0DF"><gtr:id>FE7A5770-6DF6-4825-BD56-2A5039CCD0DF</gtr:id><gtr:title>ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/77bcf36f991f182856eac148a0a0aa02"><gtr:id>77bcf36f991f182856eac148a0a0aa02</gtr:id><gtr:otherNames>Stoica R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900688</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>